Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
9.76
-0.03 (-0.31%)
Nov 21, 2024, 1:53 PM EST - Market open
Neumora Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for NMRA stock have an average target of 23.4, with a low estimate of 15 and a high estimate of 30. The average target predicts an increase of 139.75% from the current stock price of 9.76.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NMRA stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 2 | 2 |
| Buy | 3 | 4 | 4 | 4 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 8 | 8 | 8 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +207.38% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +135.66% | Nov 13, 2024 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades $18 → $15 | Buy → Hold | Downgrades | $18 → $15 | +53.69% | Nov 5, 2024 |
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +135.66% | Oct 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +207.38% | Oct 1, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.51
from -3.63
EPS Next Year
-1.58
from -1.51
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 99.7M | ||
| Avg | n/a | n/a | 37.8M | ||
| Low | n/a | n/a | 9.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.44 | -1.39 | -1.08 | ||
| Avg | -1.51 | -1.58 | -1.54 | ||
| Low | -1.54 | -1.67 | -1.98 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.